{"DataElement":{"publicId":"7122463","version":"1","preferredName":"Graft Versus Host Disease Preventive Intervention Administration Type","preferredDefinition":"Agent administered to an individual as part of Graft vs Host Disease (GVHD) prophylaxis.","longName":"GVHD_PREV_TX_TP","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"2681983","version":"1","preferredName":"Graft Versus Host Disease Preventive Intervention Administration","preferredDefinition":"An incompatibility reaction (which may be fatal) in a subject (host) of low immunological competence (deficient lymphoid tissue) who has been the recipient of immunologically competent lymphoid tissue from a donor who lacks at least one antigen possessed by the recipient host; the reaction, or disease, is the result of action of the transplanted cells against those host tissues that possess the antigen not possessed by the donor. Seen most commonly following bone marrow transplantation, acute disease is seen after 5-40 days and chronic disease weeks to months after transplantation, affecting, principally, the gastrointestinal tract, liver, and skin._Therapeutic, nutritional, environmental, social and or behavioral interventions at the societal, community, organizational or individual levels to reduce, modify or stop the course of a disease._The act of the dispensing, applying, or tendering of something to another, such as administration of a medicine.","longName":"GVHD_PRV_ADMN","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2681981","version":"1","preferredName":"Graft Versus Host Disease Preventive Intervention","preferredDefinition":"An incompatibility reaction (which may be fatal) in a subject (host) of low immunological competence (deficient lymphoid tissue) who has been the recipient of immunologically competent lymphoid tissue from a donor who lacks at least one antigen possessed by the recipient host; the reaction, or disease, is the result of action of the transplanted cells against those host tissues that possess the antigen not possessed by the donor. Seen most commonly following bone marrow transplantation, acute disease is seen after 5-40 days and chronic disease weeks to months after transplantation, affecting, principally, the gastrointestinal tract, liver, and skin.:An attempt to prevent disease.","longName":"C3063:C15843","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Graft Versus Host Disease","conceptCode":"C3063","definition":"A reaction, which may be fatal, in an immunocompromised subject (host) who has received an antigenically incompatible tissue transplant (graft) from an immunocompetent donor. The reaction is secondary to the activation of the transplanted cells against those host tissues that express an antigen not expressed by the donor, and is seen most commonly following bone marrow transplantation; acute disease is seen after 5-40 days, and chronic disease occurs weeks to months after transplantation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Preventive Intervention","conceptCode":"C15843","definition":"Therapeutic, nutritional, environmental, social and/or behavioral interventions at the societal, community, organizational or individual levels to reduce, modify or stop the course of a disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3A1889B5-158A-2594-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-14","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-09-14","modifiedBy":"ONEDATA","dateModified":"2007-09-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2320521","version":"1","preferredName":"Administration","preferredDefinition":"The act of administration.","longName":"C25409","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Administration","conceptCode":"C25409","definition":"The act of the dispensing, applying, or tendering of something to another, such as administration of a medicine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC71B93E-053F-5AD9-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-25","modifiedBy":"ONEDATA","dateModified":"2005-07-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3A1889B5-1598-2594-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-14","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-09-14","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7122458","version":"1","preferredName":"Type","preferredDefinition":"Something distinguishable as an identifiable class based on common qualities.","longName":"7122458v1.0","context":"COG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":null,"minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"6431768","version":"1","preferredName":"Other","longName":"6431768v1.00","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"762A692A-EEF7-29A1-E053-F662850A9EA9","latestVersionIndicator":"Yes","beginDate":"2018-09-18","endDate":null,"createdBy":"WINCHC","dateCreated":"2018-09-18","modifiedBy":"GDEEN","dateModified":"2024-01-22","changeDescription":null,"administrativeNotes":"2023.2.1 Alt VM added per ticket request CADSR0001995. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9B906005-D47B-21D6-E053-F662850A0C9E","beginDate":"2020-01-07","endDate":null,"createdBy":"LEEW","dateCreated":"2020-01-07","modifiedBy":"ONEDATA","dateModified":"2020-01-07","deletedIndicator":"No"},{"value":"TKI other than gilteritinib","valueDescription":"TKI other than gilteritinib","ValueMeaning":{"publicId":"7122459","version":"1","preferredName":"TKI other than gilteritinib","longName":"7122459","preferredDefinition":"TKI other than gilteritinib","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9B906005-D485-21D6-E053-F662850A0C9E","latestVersionIndicator":"Yes","beginDate":"2020-01-07","endDate":null,"createdBy":"LEEW","dateCreated":"2020-01-07","modifiedBy":"ONEDATA","dateModified":"2020-01-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9B906005-D49E-21D6-E053-F662850A0C9E","beginDate":"2020-01-07","endDate":null,"createdBy":"LEEW","dateCreated":"2020-01-07","modifiedBy":"ONEDATA","dateModified":"2020-01-07","deletedIndicator":"No"},{"value":"Early discontinuation of immunosuppression","valueDescription":"Early discontinuation of immunosuppression","ValueMeaning":{"publicId":"7122460","version":"1","preferredName":"Early discontinuation of immunosuppression","longName":"7122460","preferredDefinition":"Early discontinuation of immunosuppression","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9B906005-D4A8-21D6-E053-F662850A0C9E","latestVersionIndicator":"Yes","beginDate":"2020-01-07","endDate":null,"createdBy":"LEEW","dateCreated":"2020-01-07","modifiedBy":"ONEDATA","dateModified":"2020-01-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9B906005-D4C1-21D6-E053-F662850A0C9E","beginDate":"2020-01-07","endDate":null,"createdBy":"LEEW","dateCreated":"2020-01-07","modifiedBy":"ONEDATA","dateModified":"2020-01-07","deletedIndicator":"No"},{"value":"Donor lymphocyte infusion","valueDescription":"Donor lymphocyte infusion","ValueMeaning":{"publicId":"7122461","version":"1","preferredName":"Donor lymphocyte infusion","longName":"7122461","preferredDefinition":"Donor lymphocyte infusion","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9B906005-D4CB-21D6-E053-F662850A0C9E","latestVersionIndicator":"Yes","beginDate":"2020-01-07","endDate":null,"createdBy":"LEEW","dateCreated":"2020-01-07","modifiedBy":"ONEDATA","dateModified":"2020-01-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9B906005-D4E4-21D6-E053-F662850A0C9E","beginDate":"2020-01-07","endDate":null,"createdBy":"LEEW","dateCreated":"2020-01-07","modifiedBy":"ONEDATA","dateModified":"2020-01-07","deletedIndicator":"No"},{"value":"Tyrosine Kinase Inhibitor","valueDescription":"Tyrosine Kinase Inhibitor","ValueMeaning":{"publicId":"5127433","version":"1","preferredName":"Tyrosine Kinase Inhibitor","longName":"5127433","preferredDefinition":"Any substance that inhibits tyrosine kinase, an enzyme involved in the transduction and processing of many extracellular and intracellular signals including cell proliferation. Inhibition of tyrosine kinase may result in inhibition of cell growth and cell proliferation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tyrosine Kinase Inhibitor","conceptCode":"C1967","definition":"Any substance that inhibits tyrosine kinase, an enzyme involved in the transduction and processing of many extracellular and intracellular signals including cell proliferation. Inhibition of tyrosine kinase may result in inhibition of cell growth and cell proliferation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C5DDD88-FB7E-F93D-E050-BB89AD437D4E","latestVersionIndicator":"Yes","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"KUMMEROA","dateModified":"2023-02-01","changeDescription":null,"administrativeNotes":"2023.2.1 Alt VM added per ticket request CADSR0001995. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C0A75370-54B9-5F26-E053-4EBD850A29EB","beginDate":"2021-04-23","endDate":null,"createdBy":"LEEW","dateCreated":"2021-04-23","modifiedBy":"ONEDATA","dateModified":"2021-04-23","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9B906005-D466-21D6-E053-F662850A0C9E","latestVersionIndicator":"Yes","beginDate":"2020-01-07","endDate":null,"createdBy":"LEEW","dateCreated":"2020-01-07","modifiedBy":"LEEW","dateModified":"2021-04-23","changeDescription":"AAML1831 - WL","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Therapy type:","type":"Preferred Question Text","description":"Therapy type:","url":null,"context":"COG"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9B906005-D518-21D6-E053-F662850A0C9E","latestVersionIndicator":"Yes","beginDate":"2020-01-07","endDate":null,"createdBy":"LEEW","dateCreated":"2020-01-07","modifiedBy":"LEEW","dateModified":"2020-03-26","changeDescription":"AAML1831 - WL","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}